Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going?

Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and c...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 9; no. 6; p. 1337
Main Authors Magnani, Chiara F, Tettamanti, Sarah, Alberti, Gaia, Pisani, Ilaria, Biondi, Andrea, Serafini, Marta, Gaipa, Giuseppe
Format Journal Article
LanguageEnglish
Published Switzerland MDPI 27.05.2020
MDPI AG
Subjects
Acute Disease
acute leukemia
CAR T-cells
Clinical Trials as Topic
DNA Transposable Elements - genetics
gene transfer
Humans
immunotherapy
Leukemia - genetics
Leukemia - immunology
Receptors, Chimeric Antigen - immunology
Review
sleeping beauty
T-Lymphocytes - immunology
transposon
transposon
gene transfer
CAR T-cells
sleeping beauty
acute leukemia
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and cumbersome manufacturing processes have limited the widespread clinical implementation of CAR T-cell therapy. Here we will discuss the state of the art of the transposon-based gene transfer and its application in CAR T immunotherapy, specifically focusing on the Sleeping Beauty (SB) transposon system, as a valid cost-effective and safe option as compared to the viral vector-based systems. A general overview of SB transposon system applications will be provided, with an update of major developments, current clinical trials achievements and future perspectives exploiting SB for CAR T-cell engineering. After the first clinical successes achieved in the context of B-cell neoplasms, we are now facing a new era and it is paramount to advance gene transfer technology to fully exploit the potential of CAR T-cells towards next-generation immunotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors equally contributed as first authors.
These authors equally contributed as last authors.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells9061337